NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating potent anti-tumor ...

Scientists at deCODE genetics, a subsidiary of Amgen, reveal today in Nature Genetics associations between bipolar disorder and rare loss-of-function variants in two genes.

Scientists at deCODE genetics/Amgen have identified associations between bipolar disorder and rare loss-of-function variants ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

Transgenic animals continue to play an essential role in many aspects of zebrafish research, including the development of disease models. The most widely used system for zebrafish transgenesis is the ...

DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, emerging molecular glues, market share of individual therapies, and current ...

Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel ...

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely targeted infusions. By Gina Kolata Researchers have corrected a disease ...